Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5363-5374

  Sprouse, Alyssa A ^a   Herbert, Brittney Shea ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Breast cancer; Paclitaxel resistance; Resveratrol

Indexed keywords

CASPASE 7; CYTOCHROME P450 2C8; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RESVERATROL; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CYP2C8 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MULTIDRUG RESISTANCE PROTEIN; STILBENE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SENESCENCE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL AGING; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROME P-450 CYP2C8; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; P-GLYCOPROTEIN; PACLITAXEL; STILBENES; TUMOR STEM CELL ASSAY;

EID: 84917744524     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB and Bellanger RA: Resveratrol: potential as anticancer agent. J Diet Suppl 9: 45-56, 2012.
2. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y and Bonavida B: Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents 3: 77-93, 2003.
3. Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP, Gescher AJ and Brown K: Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 5: 205ra133, 2013.
4. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ and Brown K: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399, 2010.
5. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP and Brown K: Clinical trials of resveratrol. Ann NY Acad Sci 1215: 161-169, 2011.
6. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
7. Garvin S, Ollinger K and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231: 113-122, 2006.
8. Kim JE, Chen J and Lou Z: DBC1 is a negative regulator of SIRT1. Nature 451: 583-586, 2008.
9. Nin V, Escande C, Chini CC, Giri S, Camacho-Pereira J, Matalonga J, Lou Z and Chini EN: Role of deleted in breast cancer 1 (DBC1) in SIRT1 activation induced by protein kinase A and AMP activated protein kinase. J Biol Chem 287: 23489-234501, 2012.
10. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC, Finkel T and Deng CX: Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32: 11-20, 2008.
11. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302, 2007.
12. Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23: 6702-6711, 2004.
13. Hayashibara T, Yamada Y, Nakayama S, Harasawa H, Tsuruda K, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M and Maita T: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer 44: 193-201, 2002.
14. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M: Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35: 453-463, 2005.
15. Gupta SC, Kannappan R, Reuter S, Kim JH and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 1215: 150-160, 2011.
16. Kma L: Synergistic Effect of Resveratrol and Radiotherapy in Control of Cancers. Asian Pac J Cancer Prev 14: 6197-6208, 2013.
17. Wysocki PJ, Korski K, Lamperska K, Zaluski J and Mackiewicz A: Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 14: SC7-10, 2008.
18. McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.
19. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
20. Oliver MH, Harrison NK, Bishop JE, Cole PJ and Laurent GJ: A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 92(Pt 3): 513-518, 1989.
21. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446, 2010.
22. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
23. Munshi A, Hobbs M and Meyn RE: Clonogenic cell survival assay. Methods Mol Med 110: 21-28, 2005.
24. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903, 2002.
25. Juan ME, Wenzel U, Daniel H and Planas JM: Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 56: 4813-4818, 2008.
26. Frackowiak S, Labidi B, Hernandez-Verdun D and Bouteille M: Preservation of chromosome integrity during micronucleation induced by colchicine in PtK1 cells. Chromosoma 94: 468-474, 1986.
27. McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, O'Donovan N and Stordal B: in vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol 4: 40, 2014.
28. Delmas D, Solary E and Latruffe N: Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 18: 1100-1121, 2011.
29. Sung JY, Kim R, Kim JE and Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 101: 1738-1744, 2010.
30. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP and Sinclair DA: Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339: 1216-1219, 2013.
31. Jin Q, Yan T, Ge X, Sun C, Shi X and Zhai Q: Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 213: 88-97, 2007.
32. Fukui M, Yamabe N and Zhu BT: Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46: 1882-1891, 2010.
33. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI and El-Shemy HA: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44: 591-601, 2011.
34. Nabekura T, Kamiyama S and Kitagawa S: Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 327: 866-870, 2005.
35. Quan F, Pan C, Ma Q, Zhang S and Yan L: Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother 62: 622-629, 2008.
36. Vaclavikova R, Horsky S, Simek P and Gut I: Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 368: 200-209, 2003.